These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Quinn N; Parkes JD; Marsden CD Neurology; 1984 Sep; 34(9):1131-6. PubMed ID: 6540399 [TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Kurth MC; Tetrud JW; Tanner CM; Irwin I; Stebbins GT; Goetz CG; Langston JW Neurology; 1993 Sep; 43(9):1698-703. PubMed ID: 8414015 [TBL] [Abstract][Full Text] [Related]
5. Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data. Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD Clin Neuropharmacol; 1986; 9(2):165-81. PubMed ID: 3708602 [TBL] [Abstract][Full Text] [Related]
6. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety. Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940 [TBL] [Abstract][Full Text] [Related]
7. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Kurth MC; Tetrud JW; Irwin I; Lyness WH; Langston JW Neurology; 1993 May; 43(5):1036-9. PubMed ID: 8492922 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242 [TBL] [Abstract][Full Text] [Related]
14. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Nutt JG; Carter JH; Lea ES; Woodward WR Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720 [TBL] [Abstract][Full Text] [Related]
15. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Mouradian MM; Juncos JL; Fabbrini G; Chase TN Ann Neurol; 1987 Oct; 22(4):475-9. PubMed ID: 3435068 [TBL] [Abstract][Full Text] [Related]
16. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Nyholm D Expert Rev Neurother; 2006 Oct; 6(10):1403-11. PubMed ID: 17078781 [TBL] [Abstract][Full Text] [Related]
17. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Nutt JG; Woodward WR; Anderson JL Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849 [TBL] [Abstract][Full Text] [Related]
18. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329 [TBL] [Abstract][Full Text] [Related]
19. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial. Ondo WG; Shinawi L; Moore S Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074 [TBL] [Abstract][Full Text] [Related]